JARDIANCE® (Empagliflozin)
The content on this website is in relation to adult patients
Clinical Studies
JARDIANCE® demonstrated superiority in reducing the risk of CV death or HHF vs placebo in two heart failure trials2,3
Quick links
Indications
Heart failure
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
Type 2 diabetes
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes 1
According to the 5.1 section of the SmPC, both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.1
Chronic kidney disease
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
Indications
Heart failure
JARDIANCE® is indicated in adults for the treatment of symptomatic chronic heart failure.1
Type 2 diabetes
JARDIANCE® is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes 1
According to the 5.1 section of the SmPC, both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes.1
Chronic kidney disease
JARDIANCE® is indicated in adults for the treatment of chronic kidney disease.1
JARDIANCE showed a slower decline in kidney function compared with placebo over time2,3
JARDIANCE demonstrated efficacy in the older patients that you often see and treat in clinical practice4
The majority of patients admitted to hospital with heart failure in England are over 70 years old5*
The average age of diagnosis with heart failure in the UK is 77 years6
Pre-specified analysis by age of the primary outcome (composite of first heart failure hospitalisation or cardiovascular death) from the EMPEROR-Preserved trial:
* Hospital Episode Statistic Data 2021/22
Abbreviations
ARR: absolute risk reduction; CI: confidence interval; CV: cardiovascular; eGFR: estimated glomerular filtration rate; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; HHF: hospitalisation for heart failure; HR: hazard ratio; LVEF: left ventricular ejection fraction; NNT: number needed to treat; NT-proBNP: n-terminal pro hormone b-type natriuretic peptide; NYHA: new york heart association; RRR: relative risk reduction.
References
- JARDIANCE® (empagliflozin) Summary of Product Characteristics (SmPC). Available at: http://www.medicines.org.uk/emc/medicine/28973.
- Packer M et al. N Engl J Med. 2020;383(15):1413–1424.
- Anker SD et al. N Engl J Med. 2021;385(16):1451–1461.
- Böhm M et al. J Am Coll Cardiol. 2022;80(1):1–18.
- Data on file. Boehringer Ingelheim
- National Institute for Health and Care Excellence (NICE) 2018. Chronic heart failure in adults: diagnosis and management (NG106). Available from https://www.nice.org.uk/guidance/ng106.
PC-GB-108861 V2
February 2024